Advancing child-friendly artesunate-amodiaquine taste mask coated micro pellets to combat the threat of artemisinin resistant malaria in Africa

The project aims to progress innovative paediatric formulations of a fixed dose combination of artisunate/amodiaquine (ASAQ) and primaquine (PQ) for the treatment of malarial in children under 5 years. Both the ASAQ and PQ products have been developed supported by EU and WHO grants. This project will conduct pharmacokinetic studies and clinical evaluations in target patient populations, leading the way for regulatory approvals.